AstraZeneca drug gets breakthrough status in early lung cancer

LONDON (Reuters) - AstraZeneca said on Monday its immunotherapy drug Imfinzi had been granted "breakthrough" designation by U.S. regulators for treating non-metastatic lung cancer, following the success of the so-called Pacific trial.